J05AR19 · Anti-infectives for systemic use
Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris
Indications
Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100 000 HIV 1 RNA copies/mL (see sections 4.2, 4.4 and 5.1).
Composition
- Active substance
- emtricitabine, rilpivirine hydrochloride, tenofovir alafenamide fumarate
- International name (INN)
- emtricitabine;rilpivirine;tenofovir alafenamide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris
- Active substance
- emtricitabine, rilpivirine hydrochloride, tenofovir alafenamide fumarate